OGA and Alzheimer disease: Except for ASN90 which was orphaned after an unpublished phase 1 clinical trial in 2017 and announced re-evaluation for radiolabelling and diagnostic PET imaging purpose by its developer Asceneuron, the rest of the OGA inhibitors are still in clinical trials of different stages until more clinical results in AD patients become available to the public.